Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer (NSCLC).
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2014-12-01
|
Series: | Radiology and Oncology |
Subjects: | |
Online Access: | https://doi.org/10.2478/raon-2014-0038 |